2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Immunotherapy, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, ALL, LGL, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

3276 CD20xCD3 bispecific antibody therapy induces T cell-mediated trogocytosis and antigen loss

Aiko Matsuda, BA, Isabella Stathas, BS2, Neal Ramseier3, Ying S Hu4, Adam Yuh Lin, MD PhD5
1 Northwestern University, Chicago, Illinois, United States
2 Northwestern University, Chicago, Illinois, United States
3 University of Illinois Chicago, Chicago, Illinois, United States
4 University of Illinois Chicago, Chicago, Illinois, United States
5 Northwestern University, Chicago, Illinois, United States

Introduction: Bispecific antibodies (BsAbs) have emerged as an innovative therapy for the treatment of lymphoma. BsAbs facilitate synapse formation between cancer cells and T cells, leading to increased T cell activation and cytotoxicity. The cause of refractory and relapsed disease is under investigation. In chimeric antigen receptor (CAR) T cell therapy, trogocytosis plays an important role in target antigen loss, T cell exhaustion, and fratricide, leading to therapy failure. Trogocytosis is a process by which lymphocytes come into physical contact with a target cell and ‘nibble off’ surface proteins from those cells, expressing them on their own surface. While trogocytosis is an important process that is helpful and necessary for an effective T cell immune response, CAR T therapy and potentially BsAb therapy may increase trogocytic activity to a detrimental level. T cells taking too many antigens from the cancer cells will remove the identifying antigens from those cells, causing tumor antigen escape and potentially reducing the efficacy of these immunotherapies. Trogocytosis has not been previously reported in CD20xCD3 BsAbs used for lymphoma treatment, and its impact on response or relapse remains unclear. In this study, we present imaging and flow cytometry data demonstrating trogocytosis during BsAb therapy for lymphoma.

Methods: Naive T cells were isolated from BALB/c Mouse spleens using an EasySep™ Mouse T Cell Isolation Kit. To measure the efficacy of CD20xCD3 murine BsAb, T cells and murine A20 lymphoma cells, a mouse B-cell line, were co-cultured in PBS or different concentrations of BsAb for 48 hours. Afterward, cytotoxicity was measured by Lactate Dehydrogenase (LDH) assay. To visualize trogocytosis, A20 cells and T cells were each pan-membrane-protein labeled with different fluorescent dyes using an NHS-ester-based labeling strategy, then cocultured for 13 hours with PBS or 50 ng/mL BsAb. Cells were then fixed and imaged using epifluorescence and volumetric multispot structured illumination microscopy. To study trogocytosis, pan-membrane-protein-labeled A20 cells were cocultured with T cells, treated with PBS or 50 ng/mL BsAb, and collected at different time points. Samples were then stained for T cells using CD3, CD4 and CD8 antibodies and A20 cells using CD20, CD19, B220, and PDL1 antibodies, fixed, and analyzed by flow cytometry.

Results: After plating T cells and A20 cells together with different concentrations of BsAbs for 48 hours, we found that BsAb-induced cytotoxicity was concentration-dependent, as higher BsAb concentrations yielded higher levels of LDH release. Based on these results, 50 ng/ml was found to be a suitable dosage to study trogocytosis. Next, A20 cells and T cells, pan-membrane-labeled with distinct colors, were cocultured and treated with PBS or BsAbs. After 13 hours, the samples were fixed and imaged using 3D structured illumination microscopy. The super-resolution images showed that samples treated with BsAbs had A20 cell membrane proteins transferred onto the membrane of some T cells. These proteins were located away from the contact site, indicating that trogocytosis was occurring between T cells and A20 cells. T cells and pan-membrane-protein-labeled A20 cells were cocultured and then stained with various antibodies of interest. Samples were then run through a flow cytometer, which revealed differences between samples treated with or without BsAbs. T cells, which were established as CD3-positive during analysis, showed increased expression of CD20, CD19, B220, PDL1, and the pan-membrane-protein label as early as 1 hour in samples treated with BsAbs. These markers continued to increase on positively labeled CD3, CD4, and CD8 cells over the span of 24 hours. In the same BsAb-treated samples, A20 cells showed decreasing levels of CD20, CD19, B220, PDL1, and their own pan-membrane-protein label over the course of 24 hours. For PBS-treated samples, there was no significant increase or decrease in these markers compared with BsAb-treated samples.

Conclusion: To our knowledge, these results are the first to demonstrate that BsAbs enhance the trogocytic activity of T cells and suggest that trogocytosis is part of a resistance strategy to evade T cell-mediated cytotoxicity by antigen loss, T cell exhaustion, and possible fratricide. Further research into trogocytosis and its impact on BsAb therapy effectiveness will contribute to developing improved treatment strategies for patients.
Aiko Matsuda, BA: No relevant conflicts of interest to declare.